Source: International Congress 2016 – Mesothelioma and pleural disease: from the bench to the bedside
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
Ioannis Psallidas (Oxford, United Kingdom), Ioannis Psallidas, Nikolaos Kanellakis, Marie-Laetitia Thezenas, Philip Charles, John Corcoran, Rob Hallifax, Ambika Talwar, Ahmed Yousuf, John Wrightson, Ian Pavord, Climent Casals Pascual, Benedikt Kessler, Najib Rahman. Biological markers of successful pleurodesis for malignant pleural effusion. Eur Respir J 2016; 48: Suppl. 60, 495

Member's Comments

No comment yet.

Related content which might interest you: Association of biochemical determinants and fibrinous formation in malignant pleural effusion Source: International Congress 2016 – Malignant pleural disease: diagnosis and management Year: 2016 Detection of EpCAM-positive microparticles in pleural fluid: A new approach for the diagnosis of the tumoral origin of pleural effusions Source: International Congress 2015 – Emerging technologies for malignant pleural diseases management Year: 2015 Hemorrhagic malignant pleural effusion: Diagnosis, survival rate, and response to talc pleurodesis Source: International Congress 2014 – Diagnosis of pleural effusions and mediastinal adenopathies Year: 2014 Malignant pleural effusions Source: ISSN=1025-448x, ISBN=1-904097-25-1, page=177 Year: 2002 Yield of pleural cytology and macroscopic pleural invasion in metastatic pleural effusion Source: International Congress 2014 – Diagnosis of pleural effusions and mediastinal adenopathies Year: 2014 Expression of YKL-40 and MIP-1a proteins in exudates and transudates: Biomarkers for differential diagnosis of pleural effusions? Source: International Congress 2014 – Diagnosis of pleural effusions and mediastinal adenopathies Year: 2014 Volatile organic compounds as an early diagnostic tool for malignant pleural mesothelioma Source: International Congress 2014 – Diagnosis and treatment of pleural mesothelioma Year: 2014 Diagnostic value of pleural fluid angiopoietin-2 (Ang-2) levels, to differentiate malignant pleural effusions from benign pleural effusions Source: International Congress 2016 – Mesothelioma and malignant pleural disease Year: 2016 Medical pleuroscoy, role in undiagnosed pleural effusion and therapy for pneumothorax and recurrent pleural effusion Source: Annual Congress 2013 –Diagnosis and management of pleural and mediastinal diseases Year: 2013 Management of malignant pleural effusions Source: ERS Skills course: Multi-disciplinary care in thoracic oncology Year: 2019 Management of malignant pleural effusions Source: Eur Respir J 2001; 18: 402-419 Year: 2001 Management of malignant pleural effusions Source: Guideline 2001 Year: 2001 Thoracoscopic talc Poudrage pleurodesis for malignant effusions Source: International Congress 2015 – Interventional pulmonology for pleural diseases Year: 2015 The role of a pleural service in optimising pleural disease management Source: International Congress 2014 – Diagnosis of pleural effusions and mediastinal adenopathies Year: 2014 Role of thoracoscopic pleural lavage and brush in undiagnosed exudative pleural effusion Source: International Congress 2016 – Malignant pleural disease: diagnosis and management Year: 2016 Efficacy of cytology, cell blocks and thoracoscopic pleural biopsy in malignant pleural effusion diagnosis Source: Annual Congress 2013 –Clinical problems in mediastinal and pleural malignacies Year: 2013 Outcomes of bedside talc slurry pleurodesis for malignant pleural effusions: A retrospective analysis Source: Annual Congress 2013 –Diagnosis and management of pleural and mediastinal diseases Year: 2013 Value of thoracoscopic pleural brush in the diagnosis of exudative pleural effusion Source: International Congress 2014 – Diagnosis and treatment of pleural mesothelioma Year: 2014